ARA 290 peptide, also called cibinetide, is an experimental compound studied for its potential to help damaged nerves. Early human research gives scientists reasons to keep investigating, but it hasn’t established ARA-290 as a dependable treatment for nerve pain. Published human study

If you’ve seen claims about nerve regeneration, you probably want to know whether people actually felt better and whether that improvement lasted. Here’s what the evidence tells us.

What is ARA-290?

ARA-290 is a laboratory-made peptide, a short chain of building blocks called amino acids. Its development grew out of research into erythropoietin, or EPO, a hormone that helps your body produce red blood cells.

Scientists wanted to explore EPO’s protective effects on tissues without increasing red blood cell production. ARA-290 was designed for that purpose. Research background

You may see it written as ARA-290, ARA 290, ARA290 or cibinetide. These names refer to the same compound.

Can ARA-290 help damaged nerves?

There are early signs of a possible repair effect in small nerve fibers. These tiny nerves help you sense pain and temperature. When damaged, they can cause burning, tingling or numbness. This condition is called small fiber neuropathy.

Some studies included people with sarcoidosis, a disease in which immune cells gather into small lumps inside the body. These can interfere with how organs work, especially the lungs. Some people also develop nerve problems. NIH explanation

The cause of nerve damage matters. Results in people with sarcoidosis cannot automatically be applied to a pinched nerve, an injury or every other condition with similar symptoms.

What did the human studies actually find?

ARA-290 and sarcoidosis-related nerve problems

In a four-week study of 22 people, the ARA-290 group reported greater improvement on a nerve-symptom questionnaire. However, pain and fatigue scores, measured separately, improved similarly in people receiving a placebo, a treatment without an active drug. 2012 study

A later study of 64 people examined tiny nerves in the clear front surface of the eye and signs of nerve regrowth in skin samples. One of three treatment groups did better than the placebo group on the main nerve measurement. Pain improved across all groups, so the study didn’t clearly establish greater pain relief from ARA-290. 2017 study

That difference matters: a better nerve measurement doesn’t necessarily mean someone sleeps better, walks more comfortably or feels less pain.

ARA-290 and diabetes-related nerve problems

Another trial studied people with type 2 diabetes and painful nerve symptoms. Treatment lasted 28 days, followed by another month of observation.

The ARA-290 group improved on a nerve-symptom questionnaire. The authors also reported improvements in average blood sugar and some cholesterol-related measurements. This doesn’t establish ARA-290 as a diabetes treatment or demonstrate benefits lasting months or years. Published diabetes study

Several authors had ties to the company developing ARA-290. Larger, independent studies would help determine how dependable these findings are.

What side effects and unknowns matter?

The studies have been too small and brief to reliably identify uncommon problems or establish long-term safety.

In a small study of diabetes-related swelling at the back of the eye, headaches, nausea and head colds were considered potentially related to ARA-290. That doesn’t prove it caused each problem, but describing it as having “no side effects” would be inaccurate. Published safety findings

There also isn’t enough evidence to give dependable answers about combining it with other experimental peptides.

One online claim deserves caution: more tingling or pain means your nerves are healing. The studies reviewed here don’t establish that. New or worsening symptoms deserve medical attention rather than being dismissed as a sign that it’s working.

Is ARA-290 FDA approved, and are trials still running?

ARA-290 is not an FDA-approved treatment for nerve pain.

Its orphan drug designation for nerve pain associated with sarcoidosis encourages development for a rare condition. It does not mean the drug has passed the approval process. The FDA record specifically lists that use as unapproved.

As of October 15, 2026, our ClinicalTrials.gov search under ARA-290, ARA290 and cibinetide found no studies listed as accepting new participants. That doesn’t establish that development has ended, and there is no dependable approval date to offer. Check the current trial listings for updates.

What should you know about ARA-290 sold online?

You cannot assume that a seller’s vial contains the same material used in a clinical trial. We have not verified that any online product matches the study drug.

A laboratory report is useful only for the questions it answers. Identity, purity and sterility are different things: what the substance is, how much of the sample is that substance, and whether it contains living microbes. A purity result alone doesn’t answer all three.

Check whether the report names the laboratory, explains the tests and matches the vial’s lot number. Even then, it doesn’t establish that the product will relieve nerve pain or is suitable for someone to use.

Testimonials cannot settle those questions either. Other treatments and changes in symptoms can influence someone’s experience.

If you have nerve damage, ask your doctor whether your condition is similar to those studied and what the findings could mean for you. That’s a useful starting point for a conversation about ARA 290 peptide.

Sources

Educational notice: This page provides general information, not medical advice or instructions for preparing, injecting, dosing or combining substances. Discuss medication decisions with a qualified, licensed healthcare professional.

Author: Taylor Tides
Medical review status: Not reviewed by a licensed clinician.
Research reviewed: October 15, 2026.

ARA 290 Peptide